Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT₇) and 5-HT_1A Receptor Activity

10.1001/archpsyc.1990.01810190015002

10.1111/j.1600-0773.1982.tb01032.x

10.1007/s00213-006-0577-y

Barnes, 1998, Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia, Int Clin Psychopharmacol, 13, S49, 10.1097/00004850-199803003-00009

Bersani, 1990, 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo, Clin Neuropharmacol, 13, 500, 10.1097/00002826-199012000-00003

10.1016/S0306-4522(99)00428-5

10.1007/s00213-009-1583-7

Casey, 1996, Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models, Br J Psychiatry Suppl, 29, 32, 10.1192/S0007125000298292

10.1111/j.1471-4159.1979.tb02276.x

Ellenbroek, 1987, The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs, Psychopharmacology, 93, 343, 10.1007/BF00187254

10.1016/j.bbr.2007.08.012

10.1016/j.bbr.2007.12.020

10.1177/0269881105058378

10.1016/j.schres.2003.07.009

10.1016/j.tips.2004.07.002

10.1016/j.biopsych.2005.05.012

10.1254/jjp.53.321

10.1016/j.ejphar.2007.06.058

Kato, 1990, Binding profile of SM-9018, a novel antipsychotic candidate, Jpn J Pharmacol, 54, 478, 10.1254/jjp.54.478

10.1016/S0163-7258(97)00004-1

10.1038/sj.npp.1300027

10.1016/S0140-6736(08)61764-X

Lieberman, 1993, Understanding the mechanisms of action of atypical antipsychotic drugs: a review of compounds in use and development, Br J Psychiatry Suppl, 22, 7, 10.1192/S0007125000292544

Litchfield, 1949, A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96, 99

10.1016/S0006-3223(99)00255-3

10.1016/j.pnpbp.2003.09.010

10.1016/j.bbr.2004.04.026

10.1517/13543780802614920

Millan, 2000, Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors, J Pharmacol Exp Ther, 295, 853

Moore, 1992, The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent, J Pharmacol Exp Ther, 262, 545

10.4088/JCP.08m04905

10.1016/0091-3057(94)90451-0

10.1177/1359786806066040

10.1016/0893-133X(95)00239-A

10.1111/j.1460-9568.2004.03288.x

10.1016/j.neuropharm.2004.01.010

10.1016/S0091-3057(98)00068-9

10.1038/sj.bjp.0707005

10.1126/science.1083328

10.1016/j.bbr.2009.03.011

10.1254/jjp.45.493

10.1097/IOP.0b013e3181462a2e

10.1016/0091-3057(89)90079-8

10.1124/jpet.106.106047

To, 1995, Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain, Br J Pharmacol, 115, 107, 10.1111/j.1476-5381.1995.tb16327.x

10.1016/S0014-2999(97)01521-5

10.1016/j.neuropharm.2006.04.017

10.1163/1569391041501933

10.1073/pnas.71.5.1725